Mamidi et al. showed that neutralization of the complement regulator proteins CD46, CD55, and CD59 enhanced the complement-mediated activities of trastuzumab and pertuzumab in HER2+ tumor cells [215]. This evidence concerns the gene ERBB2 and neoplasm.